3 unknown. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Unknown 3 |
| Phase 3 | 1 | Unknown 1 |
Follow Forxiga: new trials by email Literature Review of Forxiga trials Research Report on Forxiga
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cardiometabolic Effects of Dapagliflozin in Heart Failure With Reduced or Mildly Reduced Ejection Fraction Dapagliflozin - Heart Failure, Reduced Ejection Fraction | Phase 2 | Unknown | Assistance Publique - Hôpitaux de Paris | 40 | 2022-06-26 | 2022-12-09 |
| Dapagliflozin Effect in Cognitive Impairment in Stroke Trial Dapagliflozin 10mg Tab, Statins (Cardiovascular Agents), Platelet Antiaggregant - Stroke, Ischemic, Mild Cognitive Impairment | Phase 2 / Phase 3 | Unknown | Jaime Daniel Mondragon | 270 | 2020-08-01 | 2022-10-04 |
| Value of SGLT2 Inhibitor (Dapagliflozin) as an Added Therapy in Diabetic Patients With Heart Failure With Reduced Ejection Fraction; Randomized Controlled Clinical Trial Dapagliflozin 10 MG, Placebo oral tablet - Heart Failure With Reduced Ejection Fraction (HFrEF), Diabete Type 2 | Phase 2 | Unknown | Damanhour University | 60 | 2020-03-01 | 2020-03-11 |
Cardiomyopathies (1) · Cognitive Dysfunction (1) · Dementia, Vascular (1) · Diabetes Mellitus, Type 2 (1) · Fibrosis (1) · Heart Failure (1) · Ischemic Stroke (1) · Metabolic Syndrome (1)
Assistance Publique - Hôpitaux de Paris (1) · Damanhour University (1) · Jaime Daniel Mondragon (1)
France (1) · Mexico (1)
PMID 20204386, PMID 23040716, PMID 28095900, PMID 28950419, PMID 29016744, PMID 29371333, PMID 29446769, PMID 29573529, PMID 31236801, PMID 31248555, PMID 31535829, PMID 32115470, PMID 32144994, PMID 32178931, PMID 32317958, PMID 32352644, PMID 32559474, PMID 32854852, PMID 33030307, PMID 33282811, PMID 33894597, PMID 34813630